肝素结合蛋白诊断脓毒症的准确性:系统评价与Meta分析
该系统评价与Meta分析纳入26项队列或病例对照研究、共3868例疑似脓毒症成人患者,评估血清肝素结合蛋白的诊断准确性。汇总灵敏度0.85(95%CI 0.79-0.90)、特异度0.91(95%CI 0.82-0.96),异质性低(I2=12%),未检出发表偏倚。与降钙素原(灵敏度0.75、特异度0.85)和C反应蛋白(灵敏度0.75、特异度0.71)相比,肝素结合蛋白的灵敏度和特异度均更高。连续测量显示肝素结合蛋白在脓毒症诊断前至少24小时即显著升高。作者认为其诊断能力良好,未来可评估其加入多模式脓毒症识别与预后算法的增量价值。
要点
- 在疑似全身感染的成人中,肝素结合蛋白诊断脓毒症的汇总灵敏度0.85(95%CI 0.79-0.90)、特异度0.91(95%CI 0.82-0.96)。
- 与降钙素原相比,肝素结合蛋白灵敏度更高(0.85 vs 0.75)且特异度更高(0.91 vs 0.85)。
- 与C反应蛋白相比,肝素结合蛋白灵敏度更高(0.85 vs 0.75)且特异度更高(0.91 vs 0.71)。
- 连续测量显示肝素结合蛋白水平在脓毒症诊断前至少24小时即显著升高,可能有助于早期预警。
- 研究间异质性低(I2=12%),未检出发表偏倚,但纳入研究为队列和病例对照设计,仍需前瞻性验证其加入多模式算法的增量价值。
适用人群与场景
- 疑似脓毒症的成人患者(原文纳入标准为成人、疑似脓毒症并测量血清肝素结合蛋白水平者)。
- 研究场景为评估肝素结合蛋白诊断脓毒症准确性的队列研究和病例对照研究,未限定急诊、ICU或院前具体场景。
诊断标准与关键阈值
- 原文未提及肝素结合蛋白诊断脓毒症的具体界值或阈值。
- 原文未提及脓毒症诊断所采用的具体标准名称或评分界值。
处置流程与药物剂量
- 原文未提及基于肝素结合蛋白的具体处置流程或药物剂量。
红旗征与不能漏的情况
- 原文未提及需要立刻处理或不能漏诊的具体红旗征。
研究设计与关键结果
- 研究类型为系统评价与Meta分析,纳入26项队列或病例对照研究,共3868例疑似脓毒症成人患者。
- 肝素结合蛋白诊断脓毒症的汇总灵敏度0.85(95%CI 0.79-0.90),汇总特异度0.91(95%CI 0.82-0.96),研究间异质性低(I2=12%),未检出发表偏倚。
- 与降钙素原相比,肝素结合蛋白灵敏度更高(0.85 vs 0.75 [95%CI 0.62-0.85]),特异度更高(0.91 vs 0.85 [95%CI 0.73-0.92])。
- 与C反应蛋白相比,肝素结合蛋白灵敏度更高(0.85 vs 0.75 [95%CI 0.65-0.84]),特异度更高(0.91 vs 0.71 [95%CI 0.63-0.77])。
- 连续测量显示肝素结合蛋白水平在脓毒症诊断前至少24小时即显著升高。
- 偏倚风险采用QUADAS-2工具评估(原文未报告具体评估结果)。
证据类型、等级与局限
- 证据类型为系统评价与Meta分析,纳入队列研究和病例对照研究。
- 局限:纳入研究为队列和病例对照设计;原文未报告各研究的具体偏倚风险评估结果;作者指出未来需前瞻性研究评估肝素结合蛋白加入多模式脓毒症识别与预后算法的增量价值。
对床旁实践的改变
- 在疑似脓毒症的成人患者中,肝素结合蛋白可作为诊断脓毒症的候选生物标志物,其汇总灵敏度和特异度均高于降钙素原和C反应蛋白。
- 连续监测肝素结合蛋白可能有助于在脓毒症诊断前至少24小时识别病情进展,但原文未给出具体监测频率或阈值。
- 原文未提供肝素结合蛋白用于启动或停止抗菌药物、液体复苏等具体临床决策的建议,不能据此改变现有处置流程。
- 肝素结合蛋白对脓毒症诊断的增量价值尚需前瞻性研究验证,不适用于替代现有诊断标准或多模式评估。
指南或共识出处
- 原文未提及
以上提炼依据论文摘要(全文未开放获取,或许可不允许翻译转载);全文请点「阅读原文」。
英文原文(摘要)· 点击展开
OBJECTIVES: Existing studies evaluating the accuracy of heparin-binding protein for the diagnosis of sepsis have been inconsistent. We conducted a systematic review and meta-analysis to assess the totality of current evidence regarding the utility of heparin-binding protein to diagnose sepsis in patients with presumed systemic infection.
DATA SOURCE: PubMed, Embase, the China National Knowledge infrastructure, and WangFang electronic database were searched from inception to December of 2019.
STUDY SELECTION: Two independent reviewers identified eligible studies. Cohort and case-control studies, which measured serum levels of heparin-binding protein among adult patients with suspected sepsis, were eligible for inclusion.
DATA EXTRACTION: Two reviewers independently extracted data elements from the selected studies. A bivariate random-effects meta-analysis model was used to synthesize the prognostic accuracy measures. Risk of bias of studies was assessed with Quality Assessment of Diagnostic Accuracy Studies 2 tool.
DATA SYNTHESIS: We identified 26 studies with 3,868 patients in the meta-analysis. Heparin-binding protein had a pooled sensitivity of 0.85 (95% CI, 0.79-0.90) and a pooled specificity of 0.91 (95% CI, 0.82-0.96) for the diagnosis of sepsis. There was low heterogeneity between the studies (I2 = 12%), and no evidence of publication bias was detected. Heparin-binding protein had a higher sensitivity and specificity when compared with procalcitonin (0.75 [95% CI, 0.62-0.85] and 0.85 [95% CI, 0.73-0.92]) as well as C-reactive protein (0.75 [95% CI, 0.65-0.84] and 0.71 [95% CI, 0.63-0.77]). Serial measurements of heparin-binding protein also showed that heparin-binding protein levels rose significantly at least 24 hours before a diagnosis of sepsis.
CONCLUSIONS: The diagnostic ability of heparin-binding protein is favorable, demonstrating both high sensitivity and specificity in predicting progression to sepsis in critically ill patients. Future studies could assess the incremental value that heparin-binding protein may add to a multimodal sepsis identification and prognostication algorithm for critically ill patients.
参考来源
- Wu YL, Yo CH, Hsu WT, et al. Accuracy of Heparin-Binding Protein in Diagnosing Sepsis: A Systematic Review and Meta-Analysis. Crit Care Med. 2021. PMID: 33196528. doi:10.1097/CCM.0000000000004738
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。